Outlook Therapeutics, Inc. (OTLK)

Get real-time Outlook Therapeutics Inc (OTLK) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

Outlook Therapeutics (OTLK) is back in focus after the FDA accepted its resubmitted Biologics License Application for ONS-5010/Lytenava as a Class 1 review, without requiring additional clinical trials. See our latest analysis for Outlook Therapeutics. That regulatory update has come alongside ...

Outlook Therapeutics Inc. stocks have been trading up by 14.16 percent after upbeat coverage of its eye-disease treatment prospects. Key Takeaways Outlook Therapeutics has resubmitted its Biologics License Application (BLA) to the U.S. FDA for ONS-5010/LYTENAVA (bevacizumab‑vikg) to treat ...

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

Outlook Therapeutics Inc. stocks have been trading up by 10.67 percent following highly positive coverage of its latest clinical progress. Key Takeaways Successful FDA appeal removes a major clinical overhang, with regulators affirming substantial evidence of effectiveness for ONS-5010/Lytenava ...